In reference to the patent: US20100273821
The pharmacological effects on each of the opioid receptors is different and the potency of available opioid agents at each of these receptors and indeed whether they have agonist or antagonist properties at each, is highly variable. It is therefore not possible to generalise beyond the agents for which the inventors have provided experimental data. Which is none. And in any case, the generality is all there in the Zagon patent, with this applicant's mentioning absence of moxifloxacin appearing to be an arbitrary attempt to enable patentability.
Therefore as far as I can see the examiner should reject all of the claims, unless I am missing something ?